QC
NMRA icon

Quadrature Capital’s Neumora Therapeutics NMRA Stock Holding History

Quadrature Capital’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.4K Sell
39,625
-45,699
-54% -$87K ﹤0.01% 1500
2026
Q1 		$166K Buy
85,324
+73,939
+649% +$192K ﹤0.01% 1156
2025
Q4 		$20.4K Buy
+11,385
New +$24.9K ﹤0.01% 1207
2025
Q2 		– Sell
-89,200
Closed -$89.6K – 1345
2025
Q1 		$89.6K Buy
+89,200
New +$153K ﹤0.01% 941

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quadrature Capital's NMRA Position: Q2 2026 in Review

Quadrature Capital reduced its Neumora Therapeutics (NMRA) stake by 54% in Q2 2026, selling an estimated $87K and leaving 39,625 shares worth $67.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1500.

Quadrature Capital first reported a position in NMRA in Q1 2025 and has held it in 4 quarters since. The position peaked at $166K in Q1 2026. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Quadrature Capital held 39,625 shares of Neumora Therapeutics worth $67.4K as of Q2 2026.
  • Quadrature Capital sold 45,699 Neumora Therapeutics shares in Q2 2026, an estimated $87K.
  • Neumora Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1500 holding.
  • Quadrature Capital first reported a position in Neumora Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Quadrature Capital's Neumora Therapeutics position peaked at $166K in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.